Nu Delhi: I ka pane ʻana i kahi manaʻo a Fresenius Medical Care, ua ʻōlelo aku ke Kōmike Loea Kūikawā (SEC) o ka Central Drugs Standard Control Organisation (CDSCO) i ka hui e waiho i ke kumu no ka ʻae ʻia me ka ʻikepili hoʻokolohua lapaʻau pae III o ka calcium chloride dihydrate a me ka ʻikepili kiaʻi ma hope o ke kūʻai aku ʻana mai nā ʻāina i ʻae ʻia no ka noʻonoʻo hou aku.
Ua waiho mua ka ʻoihana i kahi noi e hana a kūʻai aku i ka hopena calcium chloride dihydrate ma kahi nui o 100 mmol/L, i hoʻohana ʻia no ka "calcium replacement therapy in continuous renal replacement therapy (CRRT), continuous low-efficiency (daily) dialysis (CLED) a me ka therapeutic plasma exchange (TPE) me ka citrate anticoagulation. He kūpono ka huahana no nā pākeke a me nā keiki" a ua haʻi i nā kumu no ka hoʻokaʻawale ʻia mai nā hoʻokolohua lapaʻau pae III a me ka pae IV.
Ua hoʻomaopopo ke komite ua ʻāpono ʻia ka huahana ma nā ʻāina ʻEulopa e like me Pokukala, United Kingdom, Brazil, Switzerland, Palani a me Denemaka.
ʻO ka hui calcium chloride dihydrate ʻo CaCl2 2H2O, ʻo ia ka calcium chloride e loaʻa ana ʻelua mau molekala wai no kēlā me kēia anakahi o ka calcium chloride. He mea aniani keʻokeʻo ia, hiki ke hoʻoheheʻe ʻia i ka wai a hygroscopic, ʻo ia hoʻi hiki ke omo i ka makū mai ka lewa.
ʻO ka calcium chloride dihydrate kahi hui i hiki ke hoʻohana ʻia ma ke ʻano he ʻōnaehana hoʻoheheʻe e hoʻoheheʻe i ka chitin ke hoʻoheheʻe ʻia i loko o ka methanol. He kuleana koʻikoʻi kāna i ka uhaki ʻana i ke ʻano kristal o ka chitin a he nui nā noi i ke kahua o ka kemika.
Ma ka hālāwai SEC Nephrology i mālama ʻia ma Mei 20, 2025, ua loiloi ka panela i kahi manaʻo e ʻāpono i ka hana ʻana a me ke kūʻai aku ʻana o 100 mmol/L calcium chloride dihydrate infusion solution no ka hoʻohana ʻana i ka "calcium replacement therapy in continuous renal replacement therapy (CRRT), continuous low-efficiency (daily) dialysis (SLEDD), a me ka therapeutic plasma exchange (TPE) me ka citrate anticoagulation. Hōʻike ʻia ka huahana i nā pākeke a me nā keiki "a hāʻawi i ke kumu no nā hoʻokuʻu ʻana mai nā hoʻokolohua lapaʻau pae III a me IV.
Ma hope o ke kūkākūkā kikoʻī, ua ʻōlelo ke kōmike e waiho ʻia ke kumu no ka ʻāpono ʻia, a me ka ʻikepili hoʻokolohua lapaʻau pae III a me ka ʻikepili kiaʻi ma hope o ke kūʻai aku ʻana mai nā ʻāina i ʻāpono i ka lāʻau lapaʻau, i ke kōmike no ka noʻonoʻo hou aku.
E heluhelu pū: Ua ʻae ʻo CDSCO Group i ka lepili hou no ka Myozyme a Sanofi, noi i ka loiloi hoʻoponopono
He haumāna puka ʻo Kauka Divya Kolin ma ke ʻano he PharmD me ka ʻike nui ma ke ʻano lapaʻau a me ka haukapila a me nā mākau diagnostic a me ka therapeutic maikaʻi loa. Ua hana pū ʻo ia ma ke ʻano he kauka lāʻau lapaʻau oncology ma ka ʻoihana oncology ma Mysore Medical College and Research Institute. Ke alualu nei ʻo ia i kāna ʻoihana ma ka noiʻi lapaʻau a me ka hoʻokele ʻikepili lapaʻau. Ke hana nei ʻo ia me Medical Dialogue mai Ianuali 2022.
       Dr Kamal Kant Kohli, MBBS, MD, CP, is a thoracic specialist with over 30 years of experience and specializes in clinical writing. He joins Medical Dialogues as the Editor-in-Chief of Medical News. Apart from writing articles, as the Editor, he is responsible for proofreading and reviewing all medical content published in Medical Dialogues, including content from journals, research papers, medical conferences, guidelines, etc. Email: drkohli@medicaldialogues.in Contact: 011-43720751
Ua ʻike ʻia ma ka haʻawina ABYSS ʻo ka hoʻōki ʻana i nā beta-blockers ma hope o ka myocardial infarction ua hopena i ka piʻi ʻana o ke koko, ka helu o ka puʻuwai, a me nā hanana ʻino cardiovascular: …